Synergistic Induction of Interferon α through TLR-3 and TLR-9 Agonists Identifies CD21 as Interferon α Receptor for the B Cell Response

PLoS Pathogens

Volumn 9, Issue 3, 2013, Pages

  Kim, Dhohyung ^a   Niewiesk, Stefan ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; INTERLEUKIN 6; MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; ALPHA BETA INTERFERON RECEPTOR; CPG ODN 2216; IMMUNOLOGIC FACTOR; OLIGODEOXYRIBONUCLEOTIDE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE MARROW; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; IMMUNIZATION; NONHUMAN; PLASMACYTOID DENDRITIC CELL; POLYMERASE CHAIN REACTION; RAT; AGONISTS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHLOROCEBUS AETHIOPS; DENDRITIC CELL; FEMALE; GENE DELETION; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MEASLES VIRUS; METABOLISM; MOUSE; RABBIT; SIGMODONTINAE; VERO CELL LINE;

MEASLES VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNIZATION; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; MEASLES VIRUS; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; RABBITS; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, COMPLEMENT 3D; SEQUENCE DELETION; SIGMODONTINAE; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 9; VERO CELLS;

EID: 84875984845     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003233     Document Type: Article

References (56)

1. Letson GW, Shapiro CN, Kuehn D, Gardea C, Welty TK, et al. (2004) Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 144: 327-332.
2. del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WC, et al. (1997) Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 15: 1624-1630.
3. Bjorkholm B, Granstrom M, Taranger J, Wahl M, Hagberg L, (1995) Influence of high titers of maternal antibody on the serologic response of infants to diphtheria vaccination at three, five and twelve months of age. Pediatric Infect Dis 14: 846-850.
4. Englund JA, Anderson EL, Reed GF, Decker MD, Edwards KM, et al. (1995) The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 96: 580-584.
5. Dagan R, Amir J, Mijalovsky A, Kalmanovitch I, Bar-Yochai A, et al. (2000) Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis 19: 1045-1052.
6. Sormunen H, Stenvik M, Eskola J, Hovi T, (2001) Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J Med Virol 63: 305-310.
7. Trollfors B, (1997) Factors influencing antibody responses to acellular pertussis vaccines. Dev Biol Stand 89: 279-282.
8. Fulton RW, Briggs RE, Payton ME, Confer AW, Saliki JT, et al. (2004) Maternally derived humoral immunity to bovine viral diarrhea virus (BVDV) 1a, BVDV1b, BVDV2, bovine herpesvirus-1, parainfluenza-3 virus bovine respiratory syncytial virus, Mannheimia haemolytica and Pasteurella multocida in beef calves, antibody decline by half-life studies and effect on response to vaccination. Vaccine 26: 643-649.
9. Bradshaw BJ, Edwards S, (1996) Antibody isotype responses to experimental infection with bovine herpesvirus 1 in calves with colostrally derived antibody. Vet Microbiol 53: 143-151.
10. Waner T, Naveh A, Ben Meir NS, Babichev Z, Carmichael LE, (1998) Assessment of immunization response to canine distemper virus vaccination in puppies using a clinic-based enzyme-linked immunosorbant assay. Vet J 155: 171-175.
11. Waner T, Naveh A, Wudovsky I, Carmichael LE, (1996) Assessment of maternal antibody decay and response to canine parvovirus vaccination using a clinic-based enzyme-linked immunosorbent assay. J Vet Diagn Invest 8: 427-432.
12. Mondal SP, Naqi SA, (2001) Maternal antibody to infectious bronchitis virus: its role in protection against infection and development of active immunity to vaccine. Vet Immunol Immunopathol 10: 31-40.
13. Ellis JA, Gow SP, Goji N, (2010) Response to experimentally induced infection with bovine respiratory syncytial virus following intranasal vaccination of seropositive and seronegative calves. J Am Vet Med Assoc 236: 991-999.
14. van der Sluijs MT, Kuhn EM, Makoschey B, (2010) A single vaccination with an inactivated bovine respiratory syncytial virus vaccine primes the cellular immune response in calves with maternal antibody. BMC Vet Res 11: 6: 2.
15. Klinkenberg D, Moormann RJ, de Smit AJ, Bouma A, de Jong MC, (2002) Influence of maternal antibodies on efficacy of a subunit vaccine: transmission of classical swine fever virus between pigs vaccinated at 2 weeks of age. Vaccine 20: 3005-3013.
16. van Maanen C, Bruin G, de Boer-Luijtze E, Smolders G, de Boer GF, (1992) Interference of maternal antibodies with the immune response of foals after vaccination against equine influenza. Vet Q 14: 13-17.
17. Eidson CS, Thayer SG, Villegas P, Kleven SH, (1982) Vaccination of broiler chicks from breeder flocks immunized with a live or inactivated oil emulsion Newcastle disease vaccine. Poult Sci 61: 1621-1629.
18. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, et al. (2001) Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 184: 817-826.
19. Pueschel K, Tietz A, Carsillo M, Steward M, Niewiesk S, (2007) Measles virus-specific CD4 T-cell activity does not correlate with protection against lung infection or viral clearance. J Virol 81: 8571-8578.
20. Siegrist C-A, Barrios C, Martinez X, Brandt C, Berney M, et al. (1998) Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur J Immunol 28: 4138-4148.
21. Griffin DE, Pan C-H (2009) Measles: old vaccines and new vaccines. In: Griffin DE, Oldstone MBA, editors. Measles- Pathogenesis and Control. Heidelberg: Springer Verlag. pp. 191-212.
22. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, et al. (2003) Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 77: 4396-4400.
23. Permar SR, Klumpp SA, Mansfield KG, Carville AA, Gorgone DA, et al. (2004) Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis 190: 998-1005.
24. Niewiesk S (2009) Current animal models: cotton rat. In: Griffin DE, Oldstone MBA, editors. Measles- Pathogenesis and Control. Heidelberg: Springer Verlag. pp. 89-110.
25. Schlereth B, Buonocore L, Tietz A, ter Meulen V, Rose JK, et al. (2003) Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J Gen Virol 84: 2145-2151.
26. Kim D, Huey D, Oglesbee M, Niewiesk S, (2011) Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood (Cover) 117: 6143-6151.
27. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, et al. (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. PNAS 101: 5598-5603.
28. Kim D, Maritinez-Sobrido L, Choi C, Petroff N, Garcia-Sastre A, et al. (2011) Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodies. J Virol 85: 200-207.
29. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, et al. (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19: 225-234.
30. Delcayre AX, Salas F, Mathur S, Kovats K, Lotz M, et al. (1991) Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. EMBO J 10: 919-926.
31. Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, et al. (2006) Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J Immunol 177: 383-394.
32. Giordani L, Sanchez M, Libri I, Quaranta MG, Mattioli B, et al. (2009) IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production. J Leukoc Biol 86: 261-271.
33. Huggins J, Pellegrin T, Felgar RE, Wei C, Brown M, et al. (2007) CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells. Blood 109: 1611-1619.
34. Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, et al. (2004) Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 103: 3058-3064.
35. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, et al. (2001) Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470.
36. Fischer MB, Goerg S, Shen L, Prodeus AP, Goodnow CC, et al. (1998) Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 280: 582-585.
37. Ahearn JM, Fischer MB, Croix D, Goerg S, Ma M, et al. (1996) Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 4: 251-262.
38. Molina H, Holers VM, Li B, Fung Y, Mariathasan S, et al. (1996) Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A 93: 3357-3361.
39. Haas KM, Hasegawa M, Steeber DA, Poe JC, Zabel MD, et al. (2002) Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity 17: 713-723.
40. Wu X, Jiang N, Fang YF, Xu C, Mao D, et al. (2000) Impaired affinity maturation in Cr2-/- mice is rescued by adjuvants without improvement in germinal center development. J Immunol 165: 3119-3127.
41. Barrington RA, Pozdnyakova O, Zafari MR, Benjamin CD, Carroll MC, (2002) B lymphocyte memory: role of stromal cell complement and FcgammaRIIB receptors. J Exp Med 196: 1189-1199.
42. Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, et al. (2002) Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol 169: 2126-2133.
43. Reid RR, Woodcock S, Shimabukuro-Vornhagen A, Austen WG Jr, Kobzik L, et al. (2002) Functional activity of natural antibody is altered in Cr2-deficient mice. J Immunol 169: 5433-5440.
44. Kumagai Y, Kumar H, Koyama S, Kawai T, Takeuchi O, et al. (2009) Cutting Edge: TLR-Dependent viral recognition along with type I IFN positive feedback signaling masks the requirement of viral replication for IFN-{alpha} production in plasmacytoid dendritic cells. J Immunol 182: 3960-3964.
45. Schirrmacher V, Fournier P, (2009) Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol 542: 565-605.
46. Duthie MS, Windish HP, Fox CB, Reed SG, (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239: 178-196.
47. Jiang ZH, Koganty RR, (2003) Synthetic vaccines: the role of adjuvants in immune targeting. Curr Med Chem 10: 1423-1439.
48. Ghosh TK, Mickelson DJ, Fink J, Solberg JC, Inglefield JR, et al. (2006) Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell Immunol 243: 48-57.
49. Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, et al. (2002) Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 169: 375-383.
50. Couch RB, Atmar RL, Cate TR, Quarles JM, Keitel WA, et al. (2009) Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine 27: 5344-5348.
51. Farrar JD, Smith JD, Murphy TL, Leung S, Stark GR, et al. (2000) Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nat Immunol 1: 65-69.
52. Wyde PR, Moore-Poveda DK, De Clercq E, Neyts J, Matsuda A, et al. (2000) Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections. Antimicrob Agents Chemother 44: 1146-1152.
53. Ambrose MW, Wyde PR, Ewasyshyn M, Bonneau AM, Caplan B, et al. (1991) Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats. Vaccine 9: 505-511.
54. Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, et al. (2006) The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 24: 5027-5035.
55. Samulowitz U, Weber M, Weeratna R, Uhlmann E, Noll B, et al. (2010) A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides 20: 93-101.
56. Blanco JC, Pletneva L, Boukhvalova M, Richardson JY, Harris KA, et al. (2004) The cotton rat: an underutilized animal model for human infectious diseases can now be exploited using specific reagents to cytokines, chemokines, and interferons. J Interferon Cytokine Res 24: 21-28.